Considerations for the Utility of the CPIC Guideline for CYP2D6 Genotype and Codeine Therapy

被引：10
|
作者：
Crews, Kristine R. [1 ]
Caudle, Kelly E. [1 ]
Dunnenberger, Henry M. [2 ]
Sadhasivam, Senthilkumar [3 ,4 ]
Skaar, Todd C. [5 ]
机构：
[1] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA
[2] NorthShore Univ Hlth Syst, Ctr Mol Med, Evanston, IL USA
[3] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA
[4] Cincinnati Childrens Hosp Med Ctr, Dept Anesthesia, Cincinnati, OH USA
[5] Indiana Univ Sch Med, Div Clin Pharmacol, Dept Med, Indianapolis, IN 46202 USA
来源：
CLINICAL CHEMISTRY | 2015年 / 61卷 / 05期
关键词：
PHARMACOGENETICS; IMPLEMENTATION;
D O I：
10.1373/clinchem.2014.237412
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：775 / 776
页数：2
相关论文
共 50 条
  • [21] CYP2D6 genotype and reduced codeine analgesic effect in real-world clinical practice
    Daniel Carranza-Leon
    Alyson L. Dickson
    Andrea Gaedigk
    C. Michael Stein
    Cecilia P. Chung
    The Pharmacogenomics Journal, 2021, 21 : 484 - 490
  • [22] CYP2D6 Genotype and Reduced Codeine Analgesic Effect in Real-World Clinical Practice
    Leon, Daniel Carranza
    Dickson, Alyson
    Gaedigk, Andrea
    Stein, C. Michael
    Chung, Cecilia
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [23] CYP2D6 genotype and reduced codeine analgesic effect in real-world clinical practice
    Carranza-Leon, Daniel
    Dickson, Alyson L.
    Gaedigk, Andrea
    Stein, C. Michael
    Chung, Cecilia P.
    PHARMACOGENOMICS JOURNAL, 2021, 21 (04): : 484 - 490
  • [24] The effect of CYP 2D6 genotype and CYP2D6 inhibitors on tamoxifen
    Stearns, V
    Hayes, DF
    Jin, Y
    Ullmer, L
    Nguyen, A
    Storniolo, AM
    Flockhart, U
    Desta, Z
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 5S - 5S
  • [25] CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood:: Was it codeine or heroin?
    He, Y. J.
    Brockmoeller, J.
    Schmidt, H.
    Roots, I.
    Kirchheiner, J.
    JOURNAL OF ANALYTICAL TOXICOLOGY, 2008, 32 (02) : 178 - 182
  • [26] Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update
    Hicks, J. K.
    Sangkuhl, K.
    Swen, J. J.
    Ellingrod, V. L.
    Muller, D. J.
    Shimoda, K.
    Bishop, J. R.
    Kharasch, E. D.
    Skaar, T. C.
    Gaedigk, A.
    Dunnenberger, H. M.
    Klein, T. E.
    Caudle, K. E.
    Stingl, J. C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (01) : 37 - 44
  • [27] Analysis of CYP2D6 genotype and response to tetrabenazine
    Mehanna, Raja
    Hunter, Christine
    Davidson, Anthony
    Jimenez-Shahed, Joohi
    Jankovic, Joseph
    MOVEMENT DISORDERS, 2013, 28 (02) : 210 - 215
  • [28] Correlation of CYP2D6 genotype with response to tetrabenazine
    Mehanna, R.
    Hunter, C.
    Davidson, A.
    Jimenez-Shahed, J.
    Ondo, W.
    Jankovic, J.
    MOVEMENT DISORDERS, 2012, 27 : S457 - S457
  • [29] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
    Hicks, J. K.
    Bishop, J. R.
    Sangkuhl, K.
    Mueller, D. J.
    Ji, Y.
    Leckband, S. G.
    Leeder, J. S.
    Graham, R. L.
    Chiulli, D. L.
    LLerena, A.
    Skaar, T. C.
    Scott, S. A.
    Stingl, J. C.
    Klein, T. E.
    Caudle, K. E.
    Gaedigk, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (02) : 127 - 134
  • [30] CYP2D6 genotype and treatment with tricyclic antidepressants
    Tandon, K
    Schalkwyk, L
    Checkley, S
    Patel, M
    Kinirons, M
    Kerwin, RW
    McGuffin, P
    Aitchison, KJ
    AMERICAN JOURNAL OF MEDICAL GENETICS, 2002, 114 (07): : 775 - 775
12345